Followers | 4 |
Posts | 243 |
Boards Moderated | 0 |
Alias Born | 05/31/2008 |
Friday, March 14, 2014 11:29:46 AM
I could not resist asking the following question to Dr. Seymour. So my question and his answer are given below.
Dr. Seymour,
I read your letter about why we need so much drug for the TOX tests. It is unbelievable that FDA does not impose a limit on the amount of drug that needs to be dosed for TOX. For example, they could limit the max TOX test dosage to say 10 times of expected therapeutic dose. Looks like they do not have such limits since most drugs do have at least some side effects. Have you tried to request FDA to make an exception in case of Nanoviricides since this drug seems to have no known side effect and thus lethal dose may be very difficult to determine. If a personal meeting is hard to obtain may be they will answer your written request.
Thanks for the hard work by your team.
Best regards
..............................................................
Dr. Seymour's answer
It is rather bizarre, isn’t it?
We’re exploring other approaches with the assistance of our FDA consultants
In the meantime, the Aussies could care less, so by going there first, we can approach the FDA with solid human data that just may make a difference
This is the problem with any brand new technology
It’s all new ground and the FDA is a very risk-averse organization
The Thalidomide experience of 53 years ago still drives their thinking
Sincerely,
EUGENE SEYMOUR, MD, MPH
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM